Support for research on retroviral pathogenesis, treatment, and prevention
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91018C00007
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,011,769
Award facts
- Opportunity
-
- N02RC7102375 Solicitation number
- Contract value 44% obligated
-
- $5,661,061.39 Current, with exercised options
- $6,859,599.39 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $49,033 | |
| Funding Only Action | -$44,749 | |
| Funding Only Action | $9,042 | |
| Funding Only Action | $40,500 | |
| Exercise an Option | $208,000 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $326,000 | |
| Funding Only Action | $100,000 | |
| Funding Only Action | $20,000 | |
| Exercise an Option | $125,000 | |
| Funding Only Action | $50,000 | |
| Funding Only Action | $50,000 | |
| Exercise an Option | $150,000 | |
| Funding Only Action | $100,000 | |
| Funding Only Action | $200,000 | |
| Exercise an Option | $300,000 | |
| Exercise an Option | $429,471 | |
| Funding Only Action | $110,000 | |
| Funding Only Action | $280,000 | |
| Funding Only Action | $100,000 | |
| Original award | $409,471 |
Show all 21
About this award
This is a definitive, cost-plus-fixed-fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL) for support of research on retroviral pathogenesis, treatment, and prevention. The contract has a ceiling value of $6,859,599.39 and a performance period ending on January 29, 2024. The contract does not have a set-aside designation. ABL, a foreign-owned, for-profit manufacturer, specializes in the development of gene therapies, vaccines, and immunotherapies, and has extensive experience supporting federal research programs across NIH institutes. This contract represents one of ABL's numerous awards and Indefinite Delivery Vehicles (IDVs) with federal health agencies, demonstrating the company's broad capabilities in biopharmaceutical research and development.
Quick answers
Who was awarded contract 75N91018C00007?
75N91018C00007 was awarded to Advanced Bioscience Laboratories, Inc. by National Cancer Institute (National Institutes of Health) on June 1, 2018.
How much is contract 75N91018C00007 worth?
The government has obligated $3,011,769 on 75N91018C00007. Its current value, with exercised options, is $5,661,061. Its potential value, with all options, is $6,859,599.
Was contract 75N91018C00007 competed?
The extent of competition for 75N91018C00007 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award